Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOF/LDV + ribavirin in chronic hepatitis C with advanced liver disease or after liver transplant
NL-OMON40319Phase 2Active, not recruiting
- Sponsor
- Gilead Sciences
- Start
- Jul 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of sofosbuvir, ledipasvir and ribavirin in hepatitis C virus infection (4 cohorts), sponsored by Gilead Sciences. Primary endpoints: SVR12 and Safety and tolerability. Started Jul 2014; status: active, not recruiting.
02
Drugs
sofosbuvirledipasvirribavirin
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on NL-OMON40319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40319.